Table 2.
Influence of MXF on plasma biomarkers of hepatotoxicity in rat.
| Treatment groups | TBILI (mg/dL) | ALP (U/L) | AST (U/L) | ALT (U/L) |
|---|---|---|---|---|
| CTRL | 0.12 ± 0.02 | 239.8 ± 5.1 | 62.4 ± 2.1 | 21.6 ± 2.4 |
| MXF-1 | 0.18 ± 0.03 (50%)∗ | 262.0 ± 4.2 (9%)∗ | 74.2 ± 2.8 (19%)∗ | 39.4 ± 2.7 (82%)∗ |
| MXF-2 | 0.25 ± 0.02 (108%)∗ | 276.0 ± 6.5 (15%)∗ | 81.0 ± 3.7 (30%)∗ | 49.4 ± 3.1 (129%)∗ |
| MXF-3 | 0.28 ± 0.04 (133%)∗ | 310.6 ± 8.3 (30%)∗ | 87.2 ± 4.6 (40%)∗ | 52.8 ± 3.3 (144%)∗ |
TBILI: total bilirubin; ALP: alkaline phosphatase; AST: aspartate aminotransferase; ALT: alanine aminotransferase.
Values represent the mean ± SD of six replicates. ∗Significantly different from control (P < 0.05); values in parenthesis represent % of increase.